FDA NDA Filed for Zipalertinib in Rare Lung Cancer Subtype
A new drug application has been submitted for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion NSCLC under the FDA's Real-Time Oncology Review program.
A new drug application has been initiated for zipalertinib in combination with chemotherapy as a first-line treatment for non-small cell lung cancer patients harboring EGFR exon 20 insertion mutations, with the filing submitted for review under the U.S. Food and Drug Administration's Real-Time Oncology Review program, which is designed to expedite evaluation of promising cancer therapies.
The application is supported by data from the Phase 3 REZILIENT3 clinical trial, in which the zipalertinib combination regimen produced the longest median progression-free survival recorded to date among patients in the first-line EGFR exon 20 insertion NSCLC setting, according to the announcement. The milestone marks a potential advance in a patient population that has historically faced limited treatment options in the frontline context.
Read more Al Mouj Muscat Business Park Nears Full Occupancy After Sellout →
EGFR exon 20 insertion mutations represent a molecularly distinct and difficult-to-treat subset of NSCLC. Unlike more common EGFR alterations, this mutation type has proven resistant to many standard targeted therapies, making the development of effective first-line options a priority for oncology researchers and clinicians alike.
The FDA's Real-Time Oncology Review pathway allows the agency to begin evaluating submission components before a formal application is complete, potentially shortening the overall review timeline. Inclusion in this program generally signals that a therapy has demonstrated substantial preliminary evidence of clinical benefit in a serious condition.
Continue reading at GlobeNewswire - Industry News on Financial Services.
